Siemens Healthineers heads into a round of investor meetings in three European cities on Tuesday, giving management its first formal chance to answer questions on a strong finish to fiscal 2026 and a more cautious outlook for the year ahead. The company will meet investors at a UBS roadshow in Frankfurt, a J.P. Morgan roadshow in Paris and the UBS European Healthcare Conference in London on 10 November, according to its investor-relations calendar.

The meetings follow results that were solid on the top line. For fiscal 2026, Siemens Healthineers reported comparable revenue growth of 4.0%, an adjusted EBIT margin of 16.2% and adjusted EBIT of around €3.8 billion. Adjusted basic earnings per share came to €2.42, free cash flow reached around €2.4 billion and the company proposed an unchanged dividend of €1.00 per share.

The final quarter provided the momentum. Comparable revenue rose 5.9% in the three months to the end of September, the adjusted EBIT margin was 15.9% and adjusted basic earnings per share were €0.69. Free cash flow in the quarter was €703 million, and the equipment book-to-bill ratio, which compares new orders with sales, was 1.15 for the quarter and 1.14 for the full year, indicating that orders ran ahead of revenue.

Investors will want to probe the split between the divisions, because the quarter was far from even. Imaging, the largest business, delivered comparable revenue growth of 10.0% with an adjusted EBIT margin of 21.9%. Precision Therapy grew comparable revenue by 4.8% at a margin of 13.8%. Diagnostics, by contrast, saw comparable revenue fall 4.2% and recorded a margin of only 5.4%, making it the clear operational pressure point heading into the meetings.

The outlook for fiscal 2027 is the other issue likely to dominate the discussions. Management expects comparable revenue growth of between 4.0% and 5.0%, but adjusted basic earnings per share of only €2.20 to €2.40, a range that sits below the €2.42 reported for the year just closed. That combination of continued sales growth and lower earnings puts execution, cost control and margin development at the centre of the investor debate.

The company is also in the middle of a structural transition. It is initiating the carve-out of its Diagnostics business, which is to be renamed Olyrian Diagnostics, and the group brand is planned to become Healthineers, with the transition scheduled to begin in 2027. Chief executive Bernd Montag said the company closed the last fiscal year with a strong fourth quarter and was shaping its next phase with a different shareholder structure, adding that its strategy remained on track.

The shares traded at €44.51 on Lang & Schwarz at 18:06 CET on Sunday, 8 November. With the roadshows spread across Frankfurt, Paris and London, management will face the same questions three times over: how quickly Diagnostics can be steadied, whether the earnings dip in 2027 is a one-year step back, and how the carve-out and rebranding will change the company investors are being asked to value.